This study is in progress, not accepting new patients

Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss

a study on Cognition Disorders

Summary

for people ages 65-85 (full criteria)
at La Jolla, California and other locations
study started
estimated completion:

Description

Summary

The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease [AD]).

Official Title

Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)

Details

The A4 study is a clinical trial for older individuals who have evidence of amyloid plaque build-up in their brains who may be at risk for memory loss and cognitive decline due to Alzheimer's disease. The A4 study will test an anti-amyloid investigational drug in older individuals who do not yet show symptoms of Alzheimer's disease cognitive impairment or dementia with the aim of slowing memory and cognitive decline. The A4 study will also test whether anti-amyloid treatment can delay the progression of AD related brain injury on imaging and other biomarkers.

Keywords

Cognition Disorders Cognition Prevention Solanezumab

Eligibility

You can join if…

Open to people ages 65-85

  • Has a Mini-Mental State Examination (MMSE) score at screening of 25 to 30
  • Has a global Clinical Dementia Rating (CDR) scale score at screening of 0
  • Has a Logical Memory II score at screening of 6 to 18
  • Has a florbetapir positron emission tomography (PET) scan that shows evidence of brain amyloid pathology at screening
  • Has a study partner that is willing to participate as a source of information and has at least weekly contact with the participant (contact can be in-person, via telephone or electronic communication)

You CAN'T join if...

  • Is receiving a prescription acetylcholinesterase inhibitor (AChEI) and/or memantine at screening or baseline
  • Lacks good venous access, such that intravenous drug delivery or multiple blood draws would be precluded
  • Has current serious or unstable illness including cardiovascular, hepatic, renal,gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic,or hematologic disease or other conditions that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study
  • Has had a history within the last 5 years of a serious infectious disease affecting the brain (including neurosyphilis, meningitis, or encephalitis) or head trauma resulting in protracted loss of consciousness
  • Has had a history within the last 5 years of a primary or recurrent malignant disease with the exception of any in situ cancer that was appropriately treated and is being appropriately monitored, such as resected cutaneous squamous cell carcinoma in situ or in situ prostate cancer with normal prostate-specific antigen post-treatment
  • Has a known history of human immunodeficiency virus (HIV), clinically significant multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions(including, but not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis)
  • Is clinically judged by the investigator to be at serious risk for suicide
  • Has a history within the past 2 years of major depression or bipolar disorder as defined by the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM)
  • Has a history within the past 5 years of chronic alcohol or drug abuse/dependence as defined by the most current version of the DSM

Locations

  • University of California - San Diego
    La Jolla California 92037 United States
  • Institute for Memory Impairment & Neurological Disorders
    Irvine California 92697 United States
  • Syrentis Clinical Research
    Santa Ana California 92705 United States
  • Univ of California Irvine College of Medicine
    Orange California 92868 United States
  • University of Southern California School of Medicine
    Los Angeles California 90033 United States
  • University of California - Los Angeles
    Los Angeles California 90095 United States
  • Cleveland Clinic of Las Vegas
    Las Vegas Nevada 89106 United States
  • Banner Sun Health Research Institute
    Sun City Arizona 85351 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
Links
Click here for more information about this study: A Study of Solanezumab in Older Participants Who May be at Risk for Memory Loss (A4)
ID
NCT02008357
Phase
Phase 3
Study Type
Interventional
Last Updated
December 20, 2017